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Abstract
Aims, results, advantages and possible disadvantages of preoperative
chemotherapy (pCHT) for breast cancer are discussed in this review.
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and predictive statements. Tumor tissue can be analyzed before during
and after treatment in this regard recent studies investigating the re-
sponse to specific, chemotherapeutics in correlation to molecular
markers are reviewed. These approaches might enable us to identify
chemoresistance of specific tumors. Furthermore pCHT allows testing
ofchemosensitivityinvivoinanearlystage,whichmightleadtoamore
individualized cancer therapy.
Wediscussradiotherapyafterneoadjuvanttherapyandtheriskoflocal
relapse after breast conserving surgery, which was made feasible by
pCHT. It is shown how the evaluation of efficacy of new cancer drugs,
using the neoadjuvant situation, can be done more rapidly than in the
metastatic and adjuvant setting.
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Zusammenfassung
DieseÜbersichtsarbeitbeschäftigtsichmitZielen,Resultaten,Vorteilen,
Kontraindikationen und möglichen Nachteilen der präoperativen Che-
motherapie (pCHT) des Mammakarzinoms. Etablierte chemotherapeu-
tische Kombinationen werden mit neuen Pharmaka verglichen, welche
momentan und zukünftig in neoadjuvante Regime integriert werden.
DasPotentialneuererKomponentenillustrierenerstmalsunternommene
neoadjuvante Studien, in welchen Trastuzumab und konventionelle
Chemotherapeutika kombiniert wurden. Die Raten an pathohistologi-
schen Ansprechraten waren beeindruckend und unerwartet hoch. Ein
Überblick über aktuelle präoperative chemotherapeutische und immu-
notherapeutische klinische Studien wird in dieser Übersichtsarbeit
vermittelt.
AufgezeigtwerdendietherapeutischbedingtenVeränderungenetablier-
terPrognosefaktorenwiederdesaxillärenLymphknotenstatuswährend
derpCHT,diesichdarausergebendeNotwendigkeitneuePrognosemar-
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klinische Entscheidungsfindung. Es erscheint möglich, dass die Fort-
schritte der Gene Array und Protein Expressionsprofil Technologie ver-
besserte prognostische and prädiktive Aussagen ermöglichen. Tumor-
gewebe kann vor, während und nach der Therapie analysiert werden.
DiesbezüglichwerdenaktuelleArbeiten,diedasAnsprechenderTumo-
renaufbestimmteChemotherapeutikamitmolekularenMarkernkorre-
lieren, diskutiert. Diese Ansätze könnten uns die frühzeitige Identifika-
tion chemoresistenter Tumoren ermöglichen. Darüber hinaus handelt
es sich bei der pCHT um einen in vivo Chemosensitivitätstest, der in
Zukunft zu einer individualisierteren und maßgeschneiderteren Krebs-
behandlung führen könnte.
Wir diskutieren die Strahlentherapie nach neoadjuvanter Therapie und
das Risiko eines Lokalrezidivs nach brusterhaltender Chirurgie, welche
erst durch die präoperative Applikation der Chemotherapie ermöglicht
wurde.
Eswirdaufgezeigt,wiedieEvaluationundZulassungneuererKrebsthe-
rapeutika im Rahmen von präoperativen Behandlungskonzepten viel
schneller als in der metastasierten oder adjuvanten Situation erfolgen
kann.
Introduction
Originallypatientswithinflammatoryorinoperablelocally
advanced breast cancer were treated with preoperative
chemotherapy. The initial aim was down sizing and down
staging of tumors in order to allow a surgical procedure
suchasmastectomyorevenbreastconservingtreatment.
At the time being an increasing number of patients with
operable tumors is treated with pCHT [1]. In this neoad-
juvant setting tumor response to treatment can be mon-
itored. The efficacy of chemotherapeutics can be rapidly
improved which might lead to improved survival. PCHT
increases the rate of breast conserving surgery and
thereby decreases the surgical trauma subsequently re-
ducing morbidity, which may help improving the quality
of life of patients.
Review
Aims and advantages of preoperative
chemotherapy
It is a very old goal of cancer therapists to predict the tu-
mor's response to therapy. For decades diverse in vitro
approaches (tissue culture, cytotoxic assays, etc.) to test
chemosensitivity and predict response have been under-
taken. Up until now pCHT seems to be the only approach
to test chemosensitivity in vivo and yield valid answers
for breast cancer patients. The main goal of neoadjuvant
chemotherapy is still the reduction of the primary tumor
size.ItisestablishedthattheadministrationofpCHTcan
help to avoid mastectomy and allows the treatment of a
substantially higher number of patients with breast con-
serving surgery [2], [3], [4].
FormerlargerandomizedstudiesliketheNSABP(National
Surgical Adjuvant Breast and Bowel Project) 18 trial with
1523patientsthatcomparedneoadjuvantwithadjuvant
treatment were not able to prove a survival advantage
forpCHT[5],[6],[7],[8].Therewasnodifferencebetween
the adjuvant and neoadjuvant treatment arms either in
disease-freesurvival(DFS)orinoverallsurvival(OAS)[6],
[8].
There have been several trials in which the neoadjuvant
armshowedsuperiorsurvivalratesaftershorttermfollow
up.However,afterlongtermfollowupthisdifferencewas
no longer statistically significant [9], [10].
Nevertheless,recentstudiessuggestaprognosticadvant-
age for patients treated with more advanced elaborated
chemotherapyregimens[2].Preoperativechemotherapy
offers distinct advantages. One rationale is that if
chemotherapy is administered prior to surgery, the reac-
tion at the primary tumor site may be a predictive marker
ofmicrometastaticsystemicdiseaseresponse[6].Asthe
response of the primary tumor can be measured, sub-
groups of patients can be identified that need more in-
tensified treatment or eventually investigational therapy
options.
The evaluation of new cancer drugs by the response of
the primary tumor in vivo can be performed much more
rapidly than in the past, when long follow up in the
metastatic situation was needed to draw conclusions.
Another advantage of pCHT is that the study groups are
more homogeneous than study groups of patients with
metastatic disease usually are, in which metastases in
different organs and locations have to be compared with
regard to response to treatment. Pathological complete
response (pCR) can be used as end point for studies
evaluatingnewagents,whichmightallowearlierapproval
of new agents by national associations approving drugs
such as the US Food and Drug Administration. Classical
study endpoints in the adjuvant and metastatic setting
usually require years of follow up.
In the neoadjuvant setting, one can obtain tissue before
therapy and compare it with residual tissue at the time
2/15 GMS German Medical Science 2005, Vol. 3, ISSN 1612-3174
Honig et al.: State of the art of neoadjuvant chemotherapy in breast ...of definitive surgery with regard to change of biologic
molecular markers of response and resistance.
In vitro data support the idea of
neoadjuvant chemotherapy
The idea that preoperative chemotherapy has a more
powerful effect on survival compared with postoperative
chemotherapy is based on several biological premises:
Findings made by the Fisher group in various animal
modelsshowedanincreasedcellproliferationinresidual
tumorcellsaswellasanincreaseinserumgrowth-stimu-
latingfactorsaftertheremovaloftheprimarytumor[11],
[12], [13], [14]. This can cause rapid growth of meta-
stases and development of drug resistance [11], [15]. In
some of these models, neoadjuvant chemotherapy re-
versedtheeffectsofprimarytumorremoval[11],[15].The
productionofangiogenesisinhibitorsbytheprimarytumor
is thought to be one mechanism for the inhibition of
metastatictumorgrowth[16].PCHTmighthelptominim-
izemicrometastatictumorcellgrowth,whichreducesthe
potential adverse impact of primary tumor resection.
Preoperative chemotherapy facilitates
the study of cancer biology
A future direction of neoadjuvant treatment could be the
selection of patients based on the response to chemo-
therapyandbiologicalmarkerprofileoftheprimarytumor
enabling the therapist to tailor chemotherapy for each
patientindividually.Examiningtumortissuebefore,during
and after pCHT is possible and can be done by using
modern techniques such as immunohistochemistry,
fluorescence in situ hybridization, DNA microarrays, or
proteomics.
Wangetal.performedaninterestinginvestigationassess-
ing the histological features like tumor nuclear grade,
mitoticactivity,andbiomarkerexpressionprofilesinorder
topredictthepathologicresponsivenessofbreasttumors
to pCHT. The investigators concluded that the tumor
nuclear grade and the proliferative activity might predict
response to anthracycline-based chemotherapy [17].
Billgrenetal.showedthatafter3cyclesofchemotherapy
a significantly decreased proliferative activity predicted
a lower risk of tumor progression [18]. Symmans et al.
analyzed apoptotic indices after paclitaxel therapy in a
smallgroupofpatients.Theapoptoticindicesshortlyafter
chemotherapy administration were predictive for tumor
response [19]. Cleator et al. also found more apoptotic
cells after chemotherapy but this finding was not closely
related to response [20].
As in every other aspect of biomedical science novel
technologies such as cDNA microarrays ("gene chips")
have the potential to revolutionize the understanding of
response and resistance. As cDNA microarray analysis
becomesmoreaccessiblethebenefitsforcancertherapy
are improving [21]. Sorlie et al. were the first to demon-
strate that gene profiling will have implications for prog-
nostication of patients' outcome [22]. Van't Veer and
colleaguesidentifiedageneexpressionsignatureindica-
tive of a poor outcome in young women with lymph node
negative breast cancer. 117 primary breast tumors were
analyzedwithafollowupof5years,andtheauthorswere
able to predict a shorter interval to the occurrence of
distant metastases in a subgroup characterized by a
similar gene expression pattern [23]. When traditional
prognostic factors according to National Institutes of
Health and St.Gallen consensus statements were com-
pared to gene expression signature the gene based
analysis proved to be superior [23]. The Dutch group did
expand their analysis and examined lymph node positive
and negative patients in a further study of 295 patients.
Theyconfirmedthesuperiorityofgeneprofileprognostica-
tion versus conventional classification into low and high-
risk groups [24]. The gene expression profile selected
thosepatientswithahighriskofrelapsewhowouldmost
probably benefit from further chemotherapy and could
significantly reduce the number of patients who would
receiveunnecessarytreatment.Arandomizedtrialassess-
ingthisapproachwillbestartedsoonanditmightbecome
a valuable tool for prognostication in the future.
In contrast to gene expression analysis from excised tu-
mors after surgery, recently a cDNA microarray analysis
oftumorsamplesgainedbyfineneedleaspirationbefore
treatment was performed. This might help to select a
certainpCHTwithrespecttotheindividualgenesignature
[25].
The initiators of the neoadjuvant NSABP 27 trial were
well aware of the potential of tissue analysis when they
initiatedasubanalysis,depictedNSABP27R,tocorrelate
the response to molecular gene clusters [3].
Predictive factors for neoadjuvant
chemotherapy
Prediction means to anticipate the response of a tumor
toacertaintreatmentanalyzingitsbiologicalandclinical
characteristics.
In this aspect, a very recent report focused on a different
aspect of gene profiling. Chang et al. used gene expres-
sion patterns for the prediction of therapeutic response
to treatment. Results suggest that the development of a
clinical test for docetaxel sensitivity seems feasible, this
could reduce unnecessary treatment for women with
docetaxel insensitive breast cancer [26].
Llombart-Cussac et al. very recently showed that gene
expression profiling might be a reliable tool for pretreat-
ment prediction of gemcitabine/paclitaxel resistance.
They were able to predict resistance with an accuracy of
91% regarding both clinical and pathological response
[27]. Hannemann et al. found a characteristic gene sig-
nature change in tumors that responded to pCHT. Non-
responding tumors were not characterized by a specific
alteration of the gene pattern [28].
Identifying pre-treatment factors that predict chemother-
apy sensitivity would potentially allow for individually
tailored chemotherapy. Investigations with focus on con-
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Perez et al. investigated clinical as well as molecular
variables and were not able to find any statistical correl-
ation to predict response to chemotherapy [29]. Other
investigators were also not able to find such correlations
between classical markers and response to taxanes and
anthracyclines [30], [31]. The main finding of these in-
vestigations is that the probability of a pCR is highest in
patients with hormone receptor negative grade 3 tumors
[31], [32].
These findings might be useful to avoid chemotherapy in
selectedpopulationswhereotherapproaches(e.g.endo-
crine primary therapy) might be more useful. In this re-
spect a very recent trial by Semiglazov and coworkers
(2004)isinteresting.Therelativeefficacyofneoadjuvant
endocrine therapy was compared to chemotherapy in
postmenopausal women with estrogen receptor (ER)-
positive tumors. It turned out that endocrine treatment
with anastrozole was a reasonable alternative to
chemotherapywithdoxorubicinandpaclitaxel.Response
rates of the endocrine approach were superior and the
rate of breast conservation not inferior to the more toxic
chemotherapy regimen [33].
Pusztai et al. and Schneeweiss and coworkers found
contradictory results: One investigation showed that the
absence of Bcl-2 expression in prechemotherapy speci-
men was associated with more frequent complete
pathological response, whereas the other study docu-
mentedthatpresenceofBcl-2expressionwasastatistic-
ally significant predictive factor for the achievement of a
pCR[34],[35].Insummaryconventionalmarkersarenot
the most promising candidates for the improvement of
predictive factors in order to eventually select patients
for a certain cytostatic treatment.
Prognostic factors
In contrast to prediction, which tries to anticipate a tu-
mor'sresponsetotherapy,prognosticationisdealingwith
the outcome of patients based on biological and clinical
characteristics of the tumor. Adjuvant chemotherapy has
been applied for decades, and therefore long term follow
updataareavailable.Incontrasttothat,long-termexperi-
ence with patients that have received chemotherapy
preoperatively is rare. Lymph node metastases after
neoadjuvant therapy still have a prognostic value as a
predictor of the patients' outcome [36], [37]. The NSABP
18trialshowedthatthepresenceofpositivelymphnodes
after pCHT is highly correlated with an inferior outcome.
Therefore, axillary lymph node dissection even if original
lymphnodestatusisalteredbychemotherapyapplication
is necessary after neoadjuvant treatment in order to de-
termine a major prognostic factor [1].
A recently published long term analysis from the MD An-
dersongrouponpatientswithcytologicallyprovenaxillary
node metastases revealed that a complete eradication
of metastases by pCHT lead to a very favourable progno-
sis. 5- and 10-year data on DFS and OS in these cases
was excellent [38].
The NSABP 18 trial also showed a correlation between
pathologic response to primary therapy and overall sur-
vival as did Chollet et al., who presented data with 15
years of follow up [39]. Overall survival and DFS rates
were significantly higher in patients who had a pCR
compared to the group in which response was not com-
plete.Inmoststudiesundertakensofar,clinicalresponse
as well as pathological response to pCHT has turned out
to be a reliable prognostic factor [40], [41], [42], [43],
[44]. Only a few studies found little evidence that clinical
and pathological response to pCHT predicted survival
[10],[45].Gajdosetal.performedaretrospectiveanalysis
in locally advanced breast cancer and found that the
pathological response was not related to DFS and OS
[46]. The prognostic value of a pCR does not seem to be
compromised by residual ductal in situ carcinomata
(DCIS), which occur in 3% of cases [47]. A pathlogical
complete remission as defined by the NSABP is the ab-
sence of invasive tumor tissue, without respect to nodal
status and DCIS components.
Buchholz et al. showed that in patients with a poor re-
sponse to neoadjuvant chemotherapy, conventional
treatments can achieve reasonable outcomes in the
subgroups of lymph node-negative disease or estrogen
receptor (ER)-positive disease [48]. In the groups of wo-
menwithER-negativedisease,positivelymphnodesand
forthosewithprogressivediseaseduringpCHT,however,
more active/intensified systemic and local therapy regi-
menshavetobeapplied.Basedonthosefindingsinduct-
ive chemotherapy might allow to select patients who ob-
tainedsufficienttreatmentandthosewhoneeddifferent
or additional treatment.
In a setting where traditional prognostic factors are
changedduetotreatment,surrogatemarkersforprognos-
ticationhavetobeevaluated.Candidatesareoncogenes
or tumor suppressor genes, such as p53 that have been
shown to be of prognostic significance [49]. In a meta-
analysisofimmunohistochemicallyevaluatedp53expres-
sionofmorethan9000breastcancerpatients,theprog-
nostic and predictive value of p53 overexpression ap-
peared weak [50]. This could be explained by the fact
that the correlation between p53 protein accumulation
measured by immunohistochemistry, and p53 mutation
detected by sequencing is less than 75% in breast car-
cinoma [51], [52]. Using sequencing, a strong prognostic
andpredictivevalueofp53mutationshasbeenreported
in more than 25 studies involving over 6000 patients
[53]. The metaanalysis of these studies revealed that
mutationsinthep53geneareanindependentprognostic
factor for adverse DFS and OS in breast cancer patients
[54].
Proliferative activity has been evaluated before and after
pCHT by many study groups. Although the data are still
conflicting most studies found that clinical response is
associated with a reduced proliferation of breast cancer
cellsafterpCHT[20],[55],[56].AhighKi67labelingindex
before pCHT is associated with response because
chemotherapy does mostly have an impact on dividing
cells [57].
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mor response and marker expression remained weak
[57].
Bcl-2 was also thought to be a potential marker. Many
studies evaluated bcl-2 as a marker but it did not turn
out to be a significant marker for prognostication of out-
come or a good predictor of response [55], [57], [58].
New more reliable indices for response to treatment and
also for prognostication have to be investigated.
Does pCHT affect hormone receptor
expression?
Results of investigations regarding the influence of pCHT
on hormone receptor status remain non-conclusive [59],
[56], [60].Taucher et al. (2003) investigated the steroid
receptorexpressioninbreastcancerpatientsbeforeand
afterpCHT[61].Althoughthereisbroadclinicalevidence
thatadjuvantchemotherapyismoreeffectiveinhormone
receptor negative patients, Taucher et al. described a
modulation towards receptor negative cell population in-
duced by pCHT [61], [62]. The fact that receptor content
cannotlogicallybemeasuredinatumorafterapCRadds
to the problem and makes it even more difficult to finally
determine the true impact of pCHT on steroid receptor
expression.
Sentinel biopsy and neoadjuvant
chemotherapy
In spite of the increasing use of pCHT and sentinel node
biopsy, there is limited information on the feasibility and
accuracy of sentinel node biopsy (SNB) following neoad-
juvant chemotherapy. The number of studies concerned
withSNBintheneoadjuvantsettingissmallandthesmall
size of these trials probably accounts for the variability
of the estimates [63], [64], [65], [66]. But most probably
the desirable future trials evaluating SNB after pCHT will
notbeperformedwiththesameeffortsasthecomparison
of conventional axillary lymph node dissection and SNB.
Xing et al. tried to review this issue and found that 10 out
of 11 studies showed favourable results, with the ability
toidentifyasentinellymphnodein84%to98%ofcases,
and reported false negative rates ranging from 0% to
20%. The accuracy of sentinel lymph node biopsy follow-
ing preoperative chemotherapy for breast cancer ranges
from 88% to 100%. Although knowledge is based on
single institution and small trials the published literature
supportstheuseofsentinellymphnodebiopsyforassess-
mentoftheaxillainpatientswithclinicallynode-negative
disease following preoperative chemotherapy [67]. The
biggest study concerned with this issue is the NSABP B
27 trial which lead to encouraging results comparable to
the situation before systemic therapy and is consistent
with a recent meta-analysis [68], [69].
It is possible that pCHT affects the lymphatic drainage
pattern thus the sentinel node identification could be-
come more difficult. This question is of utmost import-
ance,becausesentinelnodebiopsyiffeasibleandaccur-
ate following pCHT could spare a lot of patients from ax-
illarylymphnodedissection.As30%-40%ofpatientswith
lymph node metastases including in the sentinel node
become tumor-free after the administration of neoad-
juvant chemotherapy [8], [70], [71].
Agents and new combinations for
neoadjuvant chemotherapy
WedonotexactlyknowtowhatdegreetheimprovedpCR
rate brought about by the addition of docetaxel will
translate into an improvement in OS. But we know for
sure that systemic chemotherapy fails to induce a pCR
in a least 70% of treated patients.
Most drug regimens for pCHT use standard drug regi-
mens, which have shown their high efficacy in the ad-
juvant and metastatic disease setting. The benefit of ad-
juvant therapy has been proven by multiple randomized
trials and confirmed by the Oxford Overviews in two
metaanalyses [72], [73]. Since the early study of 1974
from Bonadonna, who proved the benefits of adjuvant
chemotherapy,therapyprotocolswerechanged,andnew
drugs were introduced [74]. The addition of taxanes (do-
cetaxel or paclitaxel) to anthracycline and cyclophosph-
amide containing neoadjuvant regimens in the NSABP
27 trial with 2411 women with operable breast cancer
and other recent studies suggested a benefit [2], [3],
[75]. Pathologic complete response rates as well as clin-
ical response rates increased from 26% up to 34% and
from 40% up to 65%, respectively, not considering the
most recent smaller trials that need confirmation.
Newercombinationshavetotakedifferenttoxicityprofiles
into account. Gemcitabine, a pyrimidine analogue, has
shown activity in a variety of solid tumors with a good
toxicityprofile.Further,gemcitabineisnotcross-resistant
to anthracyclines and taxanes [76], [77]. Several phase
I/II/III studies are currently assessing gemcitabine com-
bined with anthracyclines, taxanes, and/or vinorelbine.
This is another suitable candidate for a combined
chemotherapyregimenbothintheneoadjuvantsituation
and metastatic disease. Preliminary findings demon-
stratedincreasedpCRratesandgoodtolerabilityofthese
regimens in patients with breast cancer [77], [78], [79].
For instance Schneeweis et al. 2003 reported a pCR rate
of 28% in a smaller trial combining epirubicin, docetaxel
andgemcitabine[80].Thesuccessoftrastuzumabinthe
metastatic setting and its good toxicity profile make this
drug a candidate for neoadjuvant and adjuvant ap-
proaches. At the time being, trastuzumab is being evalu-
ated in several preoperative studies in combination with
conventional chemotherapy. First toxicity trials were en-
couragingandwarrantedasubsequenttrialnamedNOAH,
which is performed by the Milan group [81].
Unprecedented pCR rates of 65.2% respectively 47%
were recently achieved in smaller trials which included
the use of trastuzumab in the neoadjuvant setting [82],
[83]. Interestingly even patients with positive hormone
receptor status achieved a pCR of 61.5% and hormone
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receptornegativepatientsarateof70%,withacombined
pCR rate of 67% in a small trial performed by the MD
Anderson group. Clearly these small trials need confirm-
ationinbiggerstudiesbuttheseareundoubtedlyinspiring
figures.
As taxanes seem to let to higher pathological response
rates they will be included in newer combinations [70].
Based on data gained from more advanced cases, in
whichcapecitabineleadtotheimprovementoftheoverall
survival, it is a possible candidate for future regimens
[84]. Fluropyrimidines had been droped from adjuvant
regimensintheearly1990,whichwasnotprimarilybased
on supporting data: As we saw the return of fluropy-
rimidines in the adjuvant setting, they will very probably
be part of future preoperative regimens.
Can the use of alternate schemes with
non-cross resistant chemotherapeutics
improve response?
One of the questions the GEPARTRIO-trial might answer
is whether the administration of a non-cross resistant
regimen(vinorelbine,capecitabine)afterpatientsdidnot
respondtoinitiallygiven2cyclesofTAC(docetaxel,doxo-
rubicin,cyclophosphamid)ismorebeneficialforpatients
than the continuation of the TAC regimen [85]. The addi-
tionofdocetaxeltotheneoadjuvantchemotherapyalmost
doubled the percentage of patients undergoing a pCR.
The addition of this non cross-resistant drug seems
reasonable although the addition did not increase the
rate of breast preservation, which was identical in both
groups [70].
Thomas et al. were able to demonstrate that the use of
alternate non-cross-resistant adjuvant chemotherapy
might be beneficial for the outcome [86]. In this smaller
trial,patientswithpoorresponsetoinitiallyadministered
threecyclesofadoxorubicin-basedregimenwererandom-
ized to further 5 cycles of VACP (vincristine, doxorubicin,
cyclophosphamide and prednisone) or to an alternate
non-cross resistant VbMF regimen (vinblastine, metho-
trexate with calcium leucovorin rescue and fluorouracil).
Differences did not reach statistical significance but pa-
tientsreceivingVbMFhadatrendtowardshigherrelapse-
free and overall survival [86].
It seems most promising to combine non-cross resistant
chemotherapeuticaldrugsfortheneoadjuvanttreatment.
This was recently confirmed by the Aberdeen trial. Al-
thoughnotstronglystatisticallypowered,theinitialresults
of this trial suggest that switching from an anthracycline-
basedregimentoataxane-basedregimenimprovesboth
the pCR rates and the 3-year survival rate [2], [4] (Figure
1).
Patients that had responded to 4 cycles of anthracycline
chemotherapy were randomized to 4 additional cycles of
anthracycline or docetaxel. Patients who turned out to
beanthracyclineresistantreceived4additionalcyclesof
docetaxelchemotherapy.Thepossibilityofinvivoassess-
ment enabled the authors to make an interesting discov-
ery.Inanthracyclineresistantpatients,switchingtoanon
cross-resistant drug like docetaxel did not improve the
response. Combining anthracyclines and taxanes in an-
thracycline sensitive patients lead to an unprecedented
high rate of pCR (Figure 1). Without applying chemother-
apy preoperatively the anthracycline resistant patients
could not have been selected at such an early stage. The
low histopathological response rate of 2% after an addi-
tional treatment with docetaxel showed that they might
becandidatesforcloserfollowupvisitsorinvestigational
drugs. This trial and the investigation by Evans et al.
suggestedthatdocetaxelmightnotimprovethepCRrate
in anthracycline-resistant disease [87].
Taking recently reported clinical trials together both re-
spondersandnon-responderstoananthracycline-based
regimen potentially derive additional benefit from cross-
over to an alternate non-cross-resistant therapy [88].
It will be important to see if the improved pCR rates are
associated with improved OS, especially in patients who
achieveacompleteresponsewithtaxanes.Thefollowup
of most studies is not long enough to state whether the
better clinical and pathological response really leads to
abetterDFSandOS.FirstpreliminaryresultsoftheAber-
deen trial after a median follow-up of 3 years suggested
anincreaseforpatientsreceivingdocetaxelafterrespond-
ing to the anthracycline-containing regimen. As it was a
comparably small study, the survival results should be
interpreted with caution [4].
Despite these promising regimens at the time being a
combinedtreatmentofananthracycline/cyclophospham-
ide/taxane regimen is the recommended neoadjuvant
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based on completed trials, in which the addition of tax-
anes lead to an increase of the pCR rates, if compared
to cases in which anthracycline-based regimens were
used alone [89].
Sequential,dose-denseandconventional
mode of chemotherapy administered
Trials in the adjuvant and neoadjuvant setting tested
different modes of chemotherapy. Sequential therapy
(onedrugatatimeratherthanconcurrently),dose-dense
therapyandconventionallyadministereddrugshavebeen
compared. Citron et al. recently presented data from a
big adjuvant trial where 1973 patients were analyzed
[90]. Sequential and conventional administration lead to
rather similar results. Only the two weekly dose intense
scheme of chemotherapy with granulocyte colony stimu-
lating factor (G-CSF) support was superior in terms of
outcomeandtoxicity.Incontrast,Jakischetal.performed
a neoadjuvant trial and compared dose intense adriamy-
cin/docetaxel to sequential adriamycin/cyclophospham-
idewithsequentialdocetaxel(AC>T)administration[91].
An interim analysis suggested far superior pCR rates for
the sequential application mode, and therefore, further
recruitment was halted. Pathologic complete response
rates achieved with AC>T lead to comparable results in
two independent trials [NSABP 27 (18.7%), GeparDUO-
study (16.1%)] [3], [91]. In the study conducted by Untch
et al. sequential application of two weekly dose intense
epirubicinandpaclitaxelyieldedabetterpCR(18%)than
epirubicin/paclitaxel (10%) given concurrently [92].
Actively recruiting trials (e.g. trials of the German Associ-
ation of Gynecological Oncology (AGO) PREPARE and
TECHNO) integrate modern concepts of treatment like
dose dense, dose intensified, sequential therapy and as
well as tumor targeting with trastuzumab in pCHT, and
will further clarify in what way to administer pCHT best.
Risk of local relapse
High tumor regression rates of approximately 70% made
pCHT the standard therapy option for women with locally
advancedorinoperablebreastcancer.Oneofthecardinal
questions is whether there are more local recurrences in
patientshavingsuccessfullybeendownstagedwithpCHT
andsubsequentlytreatedwithbreastconservingsurgery?
In a large trial on patients with operable breast cancer
with a median follow up of 8 years, no statistically signi-
ficant difference was found in local recurrence-free sur-
vival between patients with pCHT and patients treated
with adjuvant chemotherapy [93]. Long term investiga-
tions in patients with locally advanced breast tumors re-
vealed that women with a good clinical response whose
breastwasconserved,showedthelowestlocalrecurrence
rates [94]. Likewise, these patients had a better long-
term outcome with a 5-year survival of 96% [94], [95].
Women with locally advanced disease for whom
mastectomy was necessary have a weaker response to
chemotherapy and therefore have a less favorable prog-
nosis. They are at higher risk of local relapse and devel-
opment of new controlateral cancer [94], [96]. On the
other hand, Gajdos et al. did not find any correlation
between response and DFS or OS [46].
However,theriskforintramammaryrecurrenceinpatients
with breast conservation made possible by pCHT was re-
ported to be increased in several studies [8], [10]. A re-
currence rate of up to 14.5% dependent on the clinical
tumor size before pCHT has been reported [8]. This is
thought to be caused by multifocal tumor shrinkage
leading to multifocal residual disease and the difficulty
to adequately assess the surgical margins. In studies
comparing adjuvant with neoadjuvant treatment, local
recurrence rates were not increased in preoperatively
treated patients [8].
It is still a contradictory issue whether pCHT followed by
breast conserving surgery where usually a mastectomy
would have been performed is lead to a higher rate of
local recurrence [8], [10], [97].
It seems that the risk of locoregional tumor recurrence
after pCHT is largely dependent on conventional risk
factors such as tumor stage before chemotherapy and
histological parameters [98], [99]. Immunohistological
riskfactorsseemtoplayaminorrole.Chenetal.analyzed
risk factors for local-regional recurrence and ipsilateral
breast tumor recurrence in patients treated with pCHT.
Risk factors for these recurrences were advanced nodal
involvement at diagnosis, residual tumor larger than 2
cm, multifocal residual disease, and lymphovascular
space invasion [100].
Nevertheless, it has been stressed that in the case of
adjuvantaswellasinthecaseofneoadjuvantchemother-
apyadjuvantradiotherapyiscrucialtopreventintramam-
mary recurrence. Whether locoregional recurrence has
any impact on OS in patients treated with pCHT cannot
be answered at the present time. Although it is not very
likelythattheoutcomeofthesepatientsdiffersfromthat
ofpatientstreatedwithpostoperativechemotherapy.This
question will be answered by future studies.
With regard to the increased pCR rates, the importance
of surgery for the prevention recurrence has to be
stressed. One study compared complete responders to
pCHTwhowereonlytreatedwithradiotherapy,withpartial
responderswhoweretreatedwithsurgeryandradiother-
apy. The investigation showed that the patient group
treated with surgery were a lot less likely to have local
recurrence [101]. A very recent retrospective conducted
study by Shen et al. (2004) investigated patients with T4
locally advanced breast cancer treated with 4 cycles of
neoadjuvant chemotherapy, who underwent breast con-
servation therapy. The actuarial ipsilateral breast cancer
recurrence rate was rather low with 6%. The authors
concluded that a selected group of patients who experi-
ence tumor shrinkage and resolution of skin changes
with neoadjuvant chemotherapy are suitable candidates
for breast conservation therapy [102].
There is a general agreement that, despite the problem
of multifocal residual disease surgery is performed with
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not with respect to the initial margins [47].
Radiotherapy
In most studies dealing with neoadjuvant chemotherapy,
conventional postoperative radiotherapy was applied in
cases when mastectomy was omitted and breast con-
serving surgery performed. Bucholz et al. performed a
study to evaluate in which cases radiotherapy was bene-
ficial [99]. In all cases more advanced than stage III ra-
diotherapy is clearly indicated. In patients with stage II,
disease recurrences were too infrequent to clearly prove
thebenefitofradiotherapy,anotherinterestinginvestiga-
tion to illustrate the potential of radiotherapy. Gerlach et
al. demonstrated very high remission rates when pCHT
was combined with preoperative radiotherapy. Patholo-
gical complete remission rates were increased from 3%
to 42% but the significance for DFS and OS still needs to
be proven [103]. Radiotherapy after pCHT should be ad-
ministered according to the same recommendations as
for the adjuvant situation. Chest wall radiation after
mastectomy should be required based on initial tumor
size.AnincreasingnumberofpatientsexperienceapCR,
in these cases, whole breast irridiation is required after
breast-conserving surgery [104]. At present the need for
radiotherapy of the axilla after pCHT can not be based
on definitive data, but there are data that radiotherapy
is not a substitute for surgery [105].
Possible disadvantages of preoperative
chemotherapy
Traditional prognostic factors are altered due to neoad-
juvant treatment - the stage is modified. Prognostic
factors have to be reevaluated and other surrogate
markers like pCR have to be considered for patient
management and treatment decisions. There is a delay
in treatment for cases with progressive disease. Early
surgical removal of chemotherapy insensitive disease
might prevent a systemic spreading of cells giving rise to
micrometastases.
Theremayalsobecasesthatareovertreatedbyextensive
pCHTregimensespeciallyinnodenegativecasesbecause
pCHTisusuallyadministeredbeforehistologicalanalysis
ofaxillarylymphnodes.However,consideringthecurrent
recommendationsforadjuvanttherapy,wheretherapists
areinclinedtotreatmoreintensively,overtreatmentmight
onlyencounterasmallersubsetofpatients[104].Another
concern is that the likelihood of residual intraductal
components that may be left in situ during breast-con-
serving surgery might be higher in preoperatively treated
patients [106].
Solid tumor cells are not a uniform population. A tumor
consists of chemotherapy-sensitive and chemotherapy-
resistant cell populations. There is a risk that during
neoadjuvant therapy, when primary surgery is delayed,
resistant clones may proliferate and disseminate [107].
However, the rate of progressive disease on neoadjuvant
systemic therapy is <5% [108].
Inthisrespect,datafromneoadjuvanttrialsinlungcancer
patients have to be mentioned. Delay of primary radio-
therapy was detrimental for survival in those patients
[109]. In breast cancer delay of radiotherapy is not detri-
mental. Therefore this is more of a theoretical concern,
one fundamental and important result of completed
neoadjuvant trials was that the outcome of patients
treated preoperatively is not worse, when compared to
patients treated in the adjuvant setting with immediate
radiotherapy after surgery [5], [6].
Contraindications for preoperative
chemotherapy
Patients with operable disease and multiple tumors,
whose tumor responds very slowly to systemic therapy
or patients with tumors whose response is very difficult
to evaluate should not be treated with neoadjuvant ther-
apy. Patients with multiple tumors require mastectomy
regardless of response to treatment. Some authors also
claimthatinvasivemucinoustumorsandinvasivelobular
carcinomasshouldatleastnotbetreatedwithendocrine
neoadjuvant therapy due to the exceptionally slow re-
sponse of those tumors to therapy. Keeping this in mind
pCHT should be indicated with caution. Mathieu et al.
alsocametotheconclusionthatpCHTforinvasivelobular
breast cancer should be questioned, according to an ob-
served low rate of response with consequent ineligibility
for breast-conserving surgery [110].
Patients with hormone receptor positive tumors should
also be rather cautiously treated with neoadjuvant ther-
apy. Subgroup analysis of several studies revealed that
in such patients only a pCR rates of 3%-10% were
achieved. Consequently hormone receptor negativity
turned out to be an independent predictive factor for the
accomplishment of a pCR [111], [112].
Futuredirectionsofmoderntechnologies
for the neoadjuvant treatment
As there is an enormous prognostic difference between
responders and non-responders to neoadjuvant chemo-
therapy, investigators seek to discriminate between the
two groups with modern imaging techniques. Data for
flurodeoxyglucose positron emission tomography (PET)
isstillverypreliminary,butitmighthaveapredictivevalue
for the pathological response of tumors in the future
[113], [114].
At the time being we can not answer the question what
to do with patients that do not respond to pCHT. Clearly
these patients have an adverse prognosis and first at-
tempts to improve this situation aimed to increase re-
sponsebypreoperativechemoradiosensitizingstrategies
[115]. In order to overcome the problem of low response
to neoadjuvant treatment of hormone receptor positive
patientsendocrineandcytostaticagentswerecombined.
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lower doses of epirubicin, and interim results suggest
goodtherapeuticefficacyandexcellenttolerability[116].
Besides the new approaches in the field of gene expres-
sion profiling Pusztai and coworkers attempted to meas-
uretheproteomicresponseinpatientstreatedwithpCHT.
They monitored plasma protein changes attributable to
neoadjuvantly administered paclitaxel and FAC therapy.
They found a protein response in breast cancer patients
that was absent in the healthy control group. This as yet
unidentified protein could be a candidate marker of mi-
crometastatic disease after surgery [117].
Goals for future clinical trials
If you deal with preoperative chemotherapy you have to
ask for the goals and objectives of ongoing and future
trials. Naturally the improvement of pCR rates has to be
a major goal as it is the surrogate marker for survival.
However it is not the only task that should be focused on.
BecausemajorprognosticfactorsarealteredduetopCHT
other markers are needed in order to decide on the ne-
cessary intensity of therapy. Prognostic factors also have
to be improved in order to overcome the problem of
overtreatment of nodal negative patients. Therefore
markers should be capable to identify patients that need
less intensified treatment. Furthermore predictive state-
ments need to be improved to achieve that every tumor
is treated with the most efficient approach. Therefore
real progress can only be accomplished if investigators
take the identification of both prognostic and predictive
markersintoaccountwhendesigningnewtrialsforpCHT.
It is not desirable in the setting of an investigational trial
onlytocombinethemostefficientdrugsforbreastcancer
to achieve an impressing histologic response, because
this might not enlarge our future therapeutic options nor
does it allow to individualize therapy. Trials that take the
responsetoatreatmentintoaccountandthenrandomize
to alternative options as exemplified for example in the
Aberdeen trial seem more reasonable, and have the po-
tential to significantly improve our knowledge and treat-
ment efficacy. Alternative options include not only differ-
ent drugs and drug combinations but also sequential,
dose intensified as well as oral application modes.
Futuretrialsshouldalsoincludetheasservationoftumor
tissue and serum samples in order to analyze markers
of prognostication and prediction with respect to the pa-
tient's history, treatment and outcome.
Current trials and recent findings of
ongoing studies
[118]
GEPARDO: The study investigated whether the addition
ofdocetaxel(Doc)leadstoincreasedpCRrates.Preoper-
ative chemotherapy was combined with Tamoxifen in a
subset of patients.
GEPARDUO: AC and sequentially Doc proved to be super-
ior to dose-dense A/Doc. After the second analysis of
preliminary results an independent data monitoring
committee recommended to end the trial.
ECTO: Two adjuvant chemotherapy arms versus one neo-
adjuvant treatment arm. A longer duration of administra-
tionofdifferentchemotherapeuticswasleadingtobetter
results.ResultsfromtheECTOstudyandtheCALGB9344
trial suggested that only ER-negative patients benefit
from the addition of taxanes [119].
GEPARTRIO: One aspect was testing chemosensitivity in
vivo. After 2 cycles of TAC patients were stratified with
respect to response to treatment. Responders obtain al-
together 6 cycles of TAC and the others are randomized
to continue with TAC or to get vinorelbine/capecitabine
chemotherapy [120].
NOAH: This is a trial to evaluate trastuzumab in a neoad-
juvant approach. Immunotherapy is combined with con-
ventional chemotherapy.
TECHNO:Trastuzumabisadministeredpre-andpostoper-
atively.
GENARI:Exemestaneisincreasingtheefficacyofepirubi-
cinandotherchemotherapeutics[121],[122].Thisstudy
evaluates two different concentrations of epirubicin in
combination with exemestane [123].
Current trials are summarized in Table 1.
Conclusions
Various trials showed that neoadjuvant treatment of
breast cancer is a safe and effective way of treatment.
Neoadjuvant therapy is still in the developing stages to
treat operable and more advanced breast cancer. We
have learned from the chemotherapy trials that neoad-
juvanttreatmentisatooltodiscoverresistancepathways
and therefore might help to overcome them. Recent re-
sults prove the potential of neoadjuvant therapy trials for
the investigation of new cytostatic agents. Clinical out-
come and response to treatment are available after a
short period of time and biopsy material is available for
scientific evaluation. Evaluation of predictive factors and
correlation of therapy response to the genetic profile of
the tumor with modern technologies will allow improved
selection of patients with increasingly tailored therapy.
In contrast, the adjuvant therapy setting does not offer
the possibility to meticulously analyze response due to
the lack of a measurable primary tumor response. There
is little doubt that this mode of therapy will continue to
teach us new lessons about the biology and therapy of
breast cancer.
The reviewed studies used combinations of anthracyc-
lines, taxanes, platinum salts as well as or other two or
three drug combination chemotherapies. Randomized
trials are ongoing to determine the optimal dose, se-
quence, and composition of preoperative chemotherapy
regimens. With regard to daily clinical use outside of
clinical trials, four cycles of an anthracycline-containing
regimen sequenced with four cycles of a taxane given
before surgery appear to produce optimal reduction in
tumor volume [124].
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